First Quadrant L P CA cut its stake in DexCom, Inc. (NASDAQ:DXCM) by 25.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 741 shares of the medical device company’s stock after selling 249 shares during the quarter. First Quadrant L P CA’s holdings in DexCom were worth $300,000 at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. Sunbelt Securities Inc. purchased a new position in DexCom in the 4th quarter valued at about $3,062,000. Cognios Capital LLC purchased a new position in DexCom in the 1st quarter valued at about $26,000. Nvwm LLC acquired a new stake in DexCom in the 1st quarter valued at about $27,000. Duncker Streett & Co. Inc. acquired a new stake in DexCom in the 2nd quarter valued at about $41,000. Finally, Weaver Consulting Group acquired a new stake in DexCom in the 1st quarter valued at about $27,000. 97.08% of the stock is currently owned by hedge funds and other institutional investors.
DexCom stock opened at $435.54 on Friday. DexCom, Inc. has a fifty-two week low of $138.28 and a fifty-two week high of $446.50. The company has a debt-to-equity ratio of 1.28, a quick ratio of 5.41 and a current ratio of 7.58. The firm has a 50 day moving average price of $410.52 and a 200 day moving average price of $325.07. The company has a market capitalization of $41.70 billion, a PE ratio of 198.88, a price-to-earnings-growth ratio of 4.74 and a beta of 0.79.
DexCom (NASDAQ:DXCM) last posted its earnings results on Tuesday, July 28th. The medical device company reported $0.79 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.48. DexCom had a net margin of 11.93% and a return on equity of 29.01%. The firm had revenue of $451.80 million during the quarter, compared to the consensus estimate of $415.21 million. During the same quarter last year, the firm earned $0.08 EPS. The firm’s revenue for the quarter was up 34.3% on a year-over-year basis. As a group, equities research analysts forecast that DexCom, Inc. will post 2.45 earnings per share for the current year.
In related news, EVP Steven Robert Pacelli sold 1,531 shares of DexCom stock in a transaction that occurred on Thursday, July 23rd. The shares were sold at an average price of $427.31, for a total value of $654,211.61. Following the completion of the sale, the executive vice president now owns 51,482 shares in the company, valued at approximately $21,998,773.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kevin R. Sayer sold 6,000 shares of DexCom stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $344.63, for a total transaction of $2,067,780.00. The disclosure for this sale can be found here. Insiders sold a total of 63,293 shares of company stock valued at $24,266,963 in the last quarter. 0.69% of the stock is owned by insiders.
A number of analysts have commented on DXCM shares. Morgan Stanley increased their price objective on shares of DexCom from $377.00 to $428.00 and gave the company an “equal weight” rating in a report on Wednesday. Guggenheim increased their price objective on shares of DexCom from $385.00 to $395.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Wells Fargo & Co started coverage on shares of DexCom in a report on Thursday, May 14th. They issued an “equal weight” rating and a $420.00 price objective for the company. Zacks Investment Research downgraded shares of DexCom from a “buy” rating to a “hold” rating and set a $430.00 price objective for the company. in a report on Monday, June 22nd. Finally, Bank of America reiterated a “buy” rating and issued a $500.00 price objective on shares of DexCom in a report on Tuesday, July 28th. Seven equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $394.95.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
See Also: Hold Rating
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.